AzTrials
AzTrials

Periodontal DiseaseGLP1-PERIONCT07770906

Effect of GLP-1 Receptor Agonists on Periodontal Health and Response to Nonsurgical Periodontal Therapy

A study testing non-surgical periodontal therapy in people with Periodontal Disease and Obesity & Overweight, run by Cukurova University.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record

Search all trials

Trial summary

This study aims to evaluate the effects of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use on periodontal health and the response to non-surgical periodontal therapy in individuals with obesity and periodontitis. Read more about this study

Who is it for?
Any age
Conditions the study is for
Periodontal Disease, Obesity & Overweight
What is being tested?
non-surgical periodontal therapy
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
40 participants
Where
No sites listed yet
Study dates
1 Sep 2026to 1 Dec 2027
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Age between 18 and 65 years
  • Body mass index (BMI) ≥25 kg/m²
  • Presence of at least 20 functional teeth
  • Diagnosis of periodontitis
  • For the GLP-1 receptor agonist group: regular use of a GLP-1 receptor agonist for at least 3 months

Who cannot join

  • Age between 18 and 65 years
  • Body mass index (BMI) ≥25 kg/m²
  • Presence of at least 20 functional teeth
  • Diagnosis of periodontitis
  • For the GLP-1 receptor agonist group: regular use of a GLP-1 receptor agonist for at least 3 months

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

bahar alkaya contact

+05368720327

balkaya@cu.edu.tr

About this study

Official title: Effect of Glucagon-Like Peptide-1 Receptor Agonist Use on Periodontal Health and Response to Non-Surgical Periodontal Therapy

This study aims to evaluate the effects of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use on periodontal health and the response to non-surgical periodontal therapy in individuals with obesity and periodontitis.

Participants with obesity and periodontitis will be divided into two groups: those who have been using a GLP-1 RA for at least 3 months and those who are not using any medication for obesity. All participants will receive the same non-surgical periodontal treatment, including oral hygiene instruction, scaling, and root planing.

Periodontal clinical measurements and gingival crevicular fluid samples will be collected before treatment and at 3 and 6 months after treatment. The study will compare changes in periodontal health and inflammatory markers between the two groups to determine whether GLP-1 RA use is associated with periodontal health and the response to non-surgical periodontal therapy.

Read the detailed description

This prospective, controlled clinical study aims to compare periodontal clinical parameters and gingival crevicular fluid inflammatory markers between individuals with obesity and periodontitis who use GLP-1 RAs and those who do not use pharmacological treatment for obesity. The study will also evaluate and compare the clinical response to non-surgical periodontal therapy between the two groups.

A total of 40 participants with obesity and periodontitis will be included and allocated to two groups. The GLP-1 RA group will consist of 20 participants who have been regularly using a GLP-1 RA (semaglutide, liraglutide, or dulaglutide) for at least 3 months because of obesity. The control group will consist of 20 participants with obesity and periodontitis who are not using any medication for obesity.

All participants will receive the same non-surgical periodontal treatment protocol. Following the baseline periodontal examination, participants will receive oral hygiene instructions, including instruction in the modified Bass toothbrushing technique. Non-surgical periodontal therapy will be completed in two sessions under local anesthesia and will include full-mouth subgingival instrumentation and scaling and root planing using ultrasonic instruments and Gracey curettes. No adjunctive antimicrobial agents will be used. Participants in the GLP-1 RA group will continue their existing systemic GLP-1 RA treatment without modification.

Periodontal clinical assessments will include probing depth, clinical attachment level, bleeding on probing, plaque index, and gingival index. Gingival crevicular fluid samples will be collected using sterile PerioPaper® strips and stored at -80°C until analysis. Body mass index, HbA1c, and fasting blood glucose will also be evaluated using the measurements and laboratory results specified in the study protocol.

Clinical periodontal measurements and gingival crevicular fluid sampling will be performed at baseline and repeated at 3 and 6 months following non-surgical periodontal therapy. During follow-up visits, oral hygiene instructions will be reinforced, and professional supragingival cleaning will be performed when supragingival calculus accumulation is detected.

Changes in periodontal clinical parameters and gingival crevicular fluid inflammatory markers will be compared between the GLP-1 RA and control groups. The study is designed to determine whether GLP-1 RA use is associated with differences in periodontal inflammatory status and clinical response to non-surgical periodontal therapy in individuals with obesity and periodontitis.

Being tested
non-surgical periodontal therapy
Keywords
PERIODONTAL DISEASE, OBESİTY
Medical subject headings
Periodontal Diseases, Obesity, Overweight

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • non-surgical periodontal therapyProcedure or surgery

    All participants will receive oral hygiene instructions, including instruction in the modified Bass toothbrushing technique. Non-surgical periodontal therapy will be performed under local anesthesia in two sessions and will include full-mouth subgingival instrumentation and scaling and root planing using ultrasonic instruments and Gracey curettes. No adjunctive antimicrobial agents will be used.

Study groups in NCT07770906
Study groupRoleWhat they receive
Title: GLP-1 Receptor Agonist GroupActive comparatorNot described
Receives: Procedure: non-surgical periodontal therapy
Control GroupPlacebo comparatorNot described
Receives: Procedure: non-surgical periodontal therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Probing Depth

    Measured: Baseline, 3 months- 6 months

Secondary outcomes (1)
  1. Gingival Index

    Measured: Baseline, 3months- 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Aug 2026
  2. Study start1 Sep 2026 (estimated)
  3. Primary completion1 May 2027 (estimated)
  4. Study completion1 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
Participants with obesity and periodontitis will be included in two parallel groups according to their existing GLP-1 receptor agonist use. One group will consist of participants who have been using a GLP-1 receptor agonist for at least 3 months, while the control group will consist of participants who are not using any medication for obesity. Both groups will receive the same non-surgical periodontal therapy and will be followed for 6 months.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07770906
Sponsor's protocol ID
TS 168- KARAR 77
Acronym
GLP1-PERIO
Status last verified
Aug 2026
First submitted
13 Aug 2026
Last updated
20 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in